NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 09 09:38AM ET
6.79
Dollar change
-0.02
Percentage change
-0.29
%
IndexRUT P/E- EPS (ttm)-2.08 Insider Own12.90% Shs Outstand73.00M Perf Week-12.05%
Market Cap495.62M Forward P/E- EPS next Y-3.29 Insider Trans-0.58% Shs Float63.58M Perf Month0.89%
Income-149.70M PEG- EPS next Q-0.94 Inst Own99.01% Short Float12.15% Perf Quarter-63.69%
Sales161.00M P/S3.08 EPS this Y40.02% Inst Trans-0.16% Short Ratio2.70 Perf Half Y-74.76%
Book/sh9.04 P/B0.75 EPS next Y-98.22% ROA-27.37% Short Interest7.73M Perf Year-80.22%
Cash/sh13.07 P/C0.52 EPS next 5Y-7.03% ROE-60.80% 52W Range5.93 - 37.38 Perf YTD-64.58%
Dividend Est.- P/FCF- EPS past 5Y-5.32% ROI-22.39% 52W High-81.83% Beta2.34
Dividend TTM- Quick Ratio4.58 Sales past 5Y87.40% Gross Margin100.00% 52W Low14.41% ATR (14)0.73
Dividend Ex-Date- Current Ratio4.58 EPS Y/Y TTM7.38% Oper. Margin-230.43% RSI (14)36.16 Volatility10.45% 8.26%
Employees430 Debt/Eq0.02 Sales Y/Y TTM105.10% Profit Margin-92.98% Recom1.81 Target Price22.36
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q217.81% Payout- Rel Volume0.17 Prev Close6.81
Sales Surprise351.18% EPS Surprise218.16% Sales Q/Q646.25% EarningsMay 01 BMO Avg Volume2.86M Price6.79
SMA20-15.72% SMA50-26.48% SMA200-65.49% Trades Volume34,267 Change-0.29%
Date Action Analyst Rating Change Price Target Change
May-05-25Downgrade Truist Buy → Hold $11
May-02-25Downgrade TD Cowen Buy → Hold
May-02-25Downgrade Jefferies Buy → Hold $10
Mar-13-25Downgrade Goldman Buy → Neutral $70 → $15
Mar-12-25Downgrade Wedbush Outperform → Neutral $57 → $12
Mar-11-25Downgrade Oppenheimer Outperform → Perform
Dec-10-24Initiated BTIG Research Buy $69
Nov-18-24Initiated Stephens Overweight $55
Feb-28-24Reiterated Oppenheimer Outperform $95 → $80
Feb-14-24Downgrade Citigroup Buy → Neutral $36 → $55
May-04-25 04:17PM
May-02-25 09:19AM
03:03AM
May-01-25 09:40PM
08:15AM
08:00AM Loading…
08:00AM
07:00AM
Apr-29-25 10:01AM
Apr-28-25 07:00AM
06:45AM
Apr-23-25 10:44AM
Apr-21-25 07:00AM
Apr-09-25 09:43AM
09:35AM
Apr-04-25 03:38PM
12:33PM Loading…
12:33PM
07:00AM
Mar-27-25 07:00AM
Mar-21-25 12:44PM
12:37PM
12:17PM
09:26AM
Mar-20-25 10:19AM
Mar-19-25 10:59AM
09:35AM
Mar-18-25 08:05PM
Mar-17-25 09:35AM
Mar-14-25 12:15PM
Mar-13-25 10:52AM
Mar-11-25 04:06PM
11:43AM Loading…
11:43AM
07:45AM
06:45AM
Mar-04-25 04:05PM
Mar-03-25 09:55AM
Feb-14-25 12:00PM
09:55AM
Feb-12-25 02:49AM
02:06AM
Feb-11-25 08:15AM
07:00AM
Feb-10-25 07:17AM
Feb-03-25 07:00AM
Jan-21-25 04:29AM
Jan-10-25 07:00AM
Dec-11-24 05:38AM
Dec-10-24 01:23PM
09:05AM
Dec-04-24 01:19PM
Nov-27-24 07:00AM
Nov-25-24 05:35PM
Nov-19-24 09:06AM
Nov-04-24 07:00AM
Oct-31-24 03:05AM
Oct-30-24 08:10AM
07:00AM
Oct-29-24 09:10AM
Oct-23-24 08:44AM
Oct-22-24 04:05PM
Oct-21-24 07:00AM
Sep-12-24 01:18AM
Sep-05-24 12:01AM
Sep-02-24 05:22PM
Aug-29-24 07:00AM
Jul-30-24 01:53PM
08:20AM
07:00AM
Jul-22-24 08:30AM
Jul-17-24 03:06PM
08:44AM
Jul-15-24 08:00AM
Jun-27-24 09:31AM
Jun-26-24 04:36PM
Jun-24-24 04:37PM
Jun-21-24 07:00AM
Jun-17-24 07:00AM
Jun-03-24 04:30PM
May-23-24 05:00PM
May-16-24 09:10AM
08:07AM
07:01AM
06:00AM
May-09-24 04:42PM
May-08-24 08:36AM
May-07-24 01:54PM
10:27AM
08:15AM
07:00AM
May-02-24 10:00AM
07:00AM
May-01-24 12:00PM
Apr-30-24 10:30AM
Apr-26-24 10:00AM
Apr-24-24 04:30PM
Apr-11-24 04:19PM
12:25PM
09:17AM
08:06AM
07:40AM
07:17AM
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Berkowitz NoahChief Medical OfficerMar 18 '25Sale8.598,65874,372110,023Mar 19 08:06 AM
Noah BerkowitzOfficerMar 18 '25Proposed Sale8.598,65874,372Mar 18 09:50 PM
Loomis David KChief Accounting OfficerFeb 24 '25Sale16.751,21420,33418,863Feb 25 06:37 AM
Cacace Angela MChief Scientific OfficerFeb 24 '25Sale16.704,20770,23897,231Feb 25 06:35 AM
Taylor IanPresident, R&DFeb 24 '25Sale16.719,020150,752159,121Feb 25 06:33 AM
Houston John GPresident and CEOFeb 24 '25Sale16.7231,338523,8811,157,480Feb 25 06:31 AM
Ian TaylorOfficerFeb 24 '25Proposed Sale16.719,020150,730Feb 24 08:50 PM
John G HoustonOfficerFeb 24 '25Proposed Sale16.7131,338523,801Feb 24 08:48 PM
Angela M CacaceOfficerFeb 24 '25Proposed Sale16.694,20770,230Feb 24 08:46 PM
Loomis David KChief Accounting OfficerNov 07 '24Sale27.692316,3968,040Nov 12 05:34 PM